SLDB shows severe financial deterioration with operating cash flow declining 56% to -$156M and net losses widening 57% to -$117M despite increased stockholders equity.
The company is burning through cash at an accelerating rate while R&D expenses surged 45% with no successful clinical trial completions to show for the investment. The 25% decline in cash reserves combined with massive operating losses raises serious questions about the company's ability to fund operations without additional capital raises, which would further dilute existing shareholders.
SLDB's financial position shows a concerning pattern of deteriorating operations masked by external funding - while stockholders equity grew 31% and total assets increased 23% (likely from financing activities), core business metrics collapsed with revenue falling 41%, R&D expenses surging 45%, and operating cash flow declining 56% to -$156M. The company's cash position dropped 25% to $59.9M despite the apparent capital infusion, indicating an unsustainable burn rate. This combination of declining operational performance, increasing cash burn, and diminishing cash reserves while still having never completed a clinical trial signals significant financial distress requiring immediate attention from investors.
Capital expenditure jumped 76.3% — major investment cycle underway; assess returns on deployment.
Net income declined 56.7% — review whether driven by operations, interest costs, or non-recurring items.
Operating cash flow fell 56.3% — earnings quality concerns; investigate working capital changes and non-cash items.
R&D investment increased 45.5% — signals commitment to future product development, though near-term margin impact.
Revenue declined 40.6% — significant demand weakness or market share loss warrants investigation.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Equity base grew 31.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Current assets grew 30.6% — improving short-term liquidity or inventory/receivables build.
Cash decreased 25.3% — monitor burn rate and upcoming capital needs.
Asset base grew 23.3% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →